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Abstract 
Background: Lung transplantation remains the only viable treatment option for the 
majority of patients with advanced lung diseases. However, 5-year post-transplant 
survival rates remain low primarily secondary to chronic rejection.  Novel insights from 
global gene expression profiles may provide molecular phenotypes and therapeutic 
targets to improve outcomes after lung transplantation.  Methods: Whole-genome gene 
expression profiling was performed in a cohort of patients that underwent lung 
transplantation as well as healthy controls using the Affymetrix Human Exon 1.0ST 
Array. To explore the potential roles of microRNAs (miRNAs) in regulating lung 
transplantation-associated gene dysregulation, miRNA expression levels were also 
profiled in the same samples using the Exiqon miRCURY™ LNA Array. Results:  In a 
cohort of 18 lung transplant patients, 364 dysregulated genes were identified in 
Caucasian lung transplant patients relative to normal individuals. Pathway enrichment 
analysis of the dysregulated genes pointed to Gene Ontology biological processes such as 
"defense response", "immune response” and "response to wounding”. We then compared 
the expression profiles of potential regulating miRNAs, suggesting that dysregulation of a 
number of lung transplantation-associated genes (e.g., ATR, FUT8, LRRC8B, NFKBIA) 
may be attributed to the dysregulation of their respective regulating miRNAs. 
Conclusions: Following human lung transplantation, a substantial proportion of genes, 
particularly those genes involved in certain biological processes like immune response, 
were dysregulated in patients relative to their healthy counterparts. This exploratory 
analysis of the relationships between miRNAs and their gene targets in the context of 
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lung transplantation warrants further investigation and may serve as novel therapeutic 
targets in lung transplant complications. 
Keywords: lung transplant, gene expression, microRNA, pathway, gene ontology 
 
Background 
For many patients with end-stage lung diseases, lung transplantation is often the 
only remaining viable therapeutic measure (1) . The number of lung transplants is ~1,500 
on average a year in the United States, which represents ~45% of lung transplants 
performed world-wide (2). Compelling data have documented the beneficial impact of 
lung transplantation on functional status, hemodynamics, and quality of life. Less 
compelling, however, is the demonstration of a survival benefit due to significant 
constraints on long-term survival (1). 
Although short-term survival has improved via improved surgical techniques, 
donor preservation and immunosuppressive agents, long-term survival remains reduced 
after lung transplantation.  The major cause of decreased long-term survival is 
bronchiolitis obliterans syndrome (BOS), a physiological measure of chronic rejection 
after lung transplantation. Approximately 50% of lung transplant recipients will develop 
BOS by five years post transplantation. However, the pathogenesis of BOS has not been 
clearly elucidated. Both alloimmune-dependent and -independent factors have been 
suggested to contribute to BOS pathogenesis. These factors include acute rejection, 
lymphocytic bronchiolitis, acute infectious etiologies and gastroesophageal reflux disease.  
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In addition, an individual patient’s genetic make-up may also contribute to the 
prognosis after lung transplantation as well as to the development of various 
complications. Particularly, global gene expression profiling has been used to identify 
unique expression signatures in organ transplant biopsies that may help distinguish 
various outcomes such as acute rejection, acute dysfunction without rejection and well-
functioning transplants with no rejection history (3-5). For example, gene expression in 
bronchoalveolar lavage cell samples from lung transplant recipients with and without 
acute rejection on simultaneous lung biopsies was examined and specific expression 
patterns were demonstrated at defined time points after transplantation in allografts (4). 
Though not definitive and comprehensive, these studies showed the potential power of 
whole-genome microarrays to identify biomarkers of acute/chronic transplant rejection 
and development of other complications.  
Notably, gene expression itself has been demonstrated to be a complex and 
quantitative trait that varies within and between natural human populations (6-11) and is 
controlled by various genetic, epigenetic and non-genetic factors (12-15). MicroRNAs 
(miRNAs), small (21-25nt) non-coding RNA molecules, have emerged as a novel class of 
gene regulators that may affect various complex phenotypes including disease 
susceptibility and drug response (16, 17). Integrating whole-genome mRNA and miRNA 
profiles, therefore, could help elucidate the complex cellular response and its mechanisms 
in lung transplant patients, and provide novel biomarkers for the outcomes of lung 
transplantation. Specifically, we compared whole-genome transcriptional expression data 
profiled using the Affymetrix Human Exon 1.0ST Array (exon array) in peripheral blood 
mononuclear cells (PBMCs) from lung transplant patients and normal individuals. We 
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searched for any enriched pathways or biological processes involved the dysregulated 
genes in lung transplant patients. We further demonstrated that miRNAs could potentially 
play a critical role in determining the gene expression dysregulation observed in lung 
transplant patients. 
 
Methods 
Subjects and collection of PBMC samples 
 The study was approved by the Institutional Review Board of each collaborating 
institution with written informed consent obtained from all subjects, and was performed 
in accordance with the principles in the Declaration of Helsinki. PBMC samples were 
collected from 18 patients (14 Caucasian Americans and 4 African Americans) who 
underwent single-lung transplant or bilateral single-lung transplant surgery during 2005-
2008. The PBMC samples were collected 1.25-29.75 months after lung transplantation, 
representing a general patient population at the sample collection time. Control samples 
were collected from healthy individuals (27 Caucasians and 8 African Americans) with 
no diagnosis of pulmonary disorders at The University of Chicago Medical Center. Table 
1 shows the clinical characteristics of the study cohort. 
Obtaining exon array data 
 Total RNA was extracted from PBMCs and prepared using standard molecular 
biology protocols. RNA concentration and purity was determined and before gene 
expression profiling using the Affymetrix Human Exon 1.0ST Array (exon array) 
(Affymetrix, Inc., Santa Clara, CA). The microarray labeling, hybridization and 
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processing was performed at the University of Chicago Microarray Core Facility 
according to the manufacturer's protocol.  
Processing of exon array data 
 We used the experimental probe masking workflow provided by the Affymetrix 
Power Tools v.1.12.0 (http://www.affymetrix.com/) to filter the probeset (exon-level) 
intensity files by removing probes that contain known SNPs in the dbSNP database v129 
(18, 19). The resulting probe signal intensities were quantile normalized over all samples, 
summarized with the robust multi-array average (RMA) algorithm (20) and log2 
transformed with a median polish (19) for ~22,000 transcript clusters (gene-level) with 
the core set (i.e., with RefSeq-supported annotations) (21). Adjustment for possible batch 
effect was conducted by COMBAT (http://jlab.bu.edu/ComBat/) (22). We consider a 
transcript cluster to be reliably expressed if the DABG (detection above ground) (23) p-
value computed by the Affymetrix Power Tools was less than 0.01 in at least 80% of the 
samples in each test group (healthy controls or patients) in each population, respectively. 
We further limited our analysis set to the genes with unambiguous annotations by 
Affymetrix. Totally, 11,461 and 11,576 transcript clusters in the Caucasian American and 
African American samples, respectively, met these criteria and were further analyzed. We 
have deposited the raw and processed exon array data in the NCBI Gene Expression 
Omnibus (GEO) (Accession Number: GSE49081). 
Obtaining miRNA expression data 
 The expression levels of miRNAs were profiled using the Exiqon miRCURY™ 
LNA Array v10.0 (∼700 human miRNAs, updated to miRBase 11.0 annotation) (24) 
 7 
(Exiqon, Inc., Denmark). Briefly, total RNA from PBMCs was extracted and prepared 
according to manufacturer's protocol. Array hybridization was performed by Exiqon with 
the quantified signals background corrected using normexp with offset value 10 based on 
a convolution model (25) and normalized using the global Lowess regression algorithm. 
In total, 318 miRNAs and 309 miRNAs were found to be expressed in the Caucasian 
American samples and the African American samples, respectively (i.e., present in at 
least 80% of total samples in each population).  
Identifying genes dysregulated in patients with lung transplants 
 We excluded genes on chromosomes X and Y to avoid the potential confounding 
effect of gender. SAM (Significance Analysis of Microarrays) (26), implemented in the 
samr library of the R Statistical Package (27), was used to identify differential genes 
between patients who underwent lung transplantation and healthy controls in the 
Caucasian American and African American samples, respectively, as well as between 
patients with and without development of BOS. Transcripts with a greater than 1.5 fold-
change and q-value (28) less than 0.01 (i.e., 1% FDR, false discovery rate) were deemed 
significantly dysregulated. We searched for any enriched pathways and biological 
processes among the differential genes relative to the respective analysis set using the 
DAVID (Database for Annotation, Visualization and Integrated Discovery) tool (29, 30). 
The following databases were included: KEGG (Kyoto Encyclopedia of Genes and 
Genomes) (31), BioCarta (http://www.biocarta.com/), Reactome (32), PANTHER (33), 
and Gene Ontology (GO) (34).  Due to the exploratory nature of this study, we chose to 
use a relatively lenient cutoff, i.e., FDR<25% after the Benjamini-Horchberg procedure 
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(35) and a minimum of 5 differential genes in a pathway or biological process, for the 
DAVID analysis. 
Identifying relationships between dysregulated genes and potential regulating miRNAs 
The differential genes were then searched against the MicroCosm Targets (24) 
(i.e., miRanda algorithm) through our ExprTarget database 
(http://www.scandb.org/apps/microrna/) (36) for potential regulating miRNAs (miRanda 
p<1.010-4). Only human miRNAs that are expressed in these samples (318 miRNAs in 
the Caucasian samples; 309 miRNAs in the African American samples) were included in 
the analysis. The expression patterns of those miRNAs and their corresponding gene 
targets were compared between patients and normal controls using standard t-test. 
Significant miRNA-mRNA relationships (i.e., negative association between miRNA and 
mRNA at t-test p<0.05) were further confirmed using linear regression. The Pearson 
correlation coefficients and the associated p-values (cutoff p<0.05) were calculated using 
the lm library of the R Statistical Package (27). 
 
Results 
Identifying genes dysregulated in patients with lung transplants 
 In total, 364 genes were differentially expressed between 14 Caucasian American 
patients with lung transplants (n=14) and normal controls (n=27) (fold-change>1.5, q-
value<0.01) with 292 down-regulated and 72 up-regulated genes (Figure 1) 
(Supplementary Table S1). By comparison, only four genes were dysregulated between 
African American cases (n=4) and normal black controls (n=8) (fold-change>1.5, q-
value<0.01) with one down-regulated gene and three up-regulated genes. In addition, no 
 9 
significant BOS-associated genes were identified at the q-value<0.01 level between 
Caucasian patients with (n=5) and without BOS (n=9), probably limited by the small 
sample size of this group of patients in our study cohort. At a looser cutoff (q-
value<0.05), this comparison revealed 884 up-regulated genes associated with BOS, 
indicating a potential trend of substantial dysregulation in patients who developed BOS. 
A larger sample size may be needed for a more reliable description of this comparison. 
We focused our downstream analyses on the more robust list of dysregulated genes in all 
patients with lung transplants relative to healthy controls, particularly in the Caucasian 
samples. 
Enriched pathways among dysregulated genes 
 DAVID analysis on the 364 dysregulated genes in Caucasian American cases 
revealed 12 enriched pathways and GO biological processes such as "response to 
bacterium", "immune response" and "response to wounding" (FDR<25%, a minimum of 
5 genes). Six known pathways and GO biological processes such as “hemostasis” and 
"blood coagulation" were enriched among the 292 down-regulated genes, while 19 GO 
biological processes such as “defense response”, “response to bacterium”, and "immune 
response" were enriched among the 72 up-regulated genes (Supplementary Table S2). 
Table 2 shows the top-ranking pathways and biological processes (FDR<10%, a 
minimum of 10 genes) for each gene group (i.e., "all dysregulated", "down-regulated" 
and "up-regulated"). In addition, analysis on the 884 potentially BOS-associated genes 
showed enrichment in pathways such as “T-cell receptor signaling pathway” and 
“apoptosis”.  
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Identifying potential regulating miRNAs for the dysregulated genes 
 We searched for potential regulating miRNAs for the dysregulated genes in lung 
transplant patients based on the predictions of the miRanda algorithm (24). Among the 
292 down-regulated genes in the Caucasian American patients, 178 miRNA-mRNA 
relationships corresponding to 95 expressed miRNAs and 78 genes were identified, while 
74 miRNA-mRNA relationships corresponding to 40 expressed miRNAs and 31 genes 
were identified in the 72-up-regulated genes (miRanda p<1.010-4). In comparison, nine 
miRNAs were identified for the single down-regulated gene, SMOX (encoding spermine 
oxidase) in the African American patients (miRanda p<1.010-4). 
 We further searched for miRNAs that showed a negatively associated expression 
pattern with their potential gene targets using t-test (Table 3). For the down-regulated 
genes in the Caucasian American patients, six potential regulating miRNAs were found 
to be up-regulated in the patients (corresponding to 8 miRNA-mRNA relationships). For 
example, hsa-miR-34a was up-regulated (t-test p=0.0001), while its gene target, FUT8 
(encoding fucosyltransferase 8) was down-regulated in transplant patients; and hsa-miR-
519e was up-regulated (t-test p=0.003), consistent with down-regulation of its potential 
targets, ATR (encoding ataxia telangiectasia and Rad3 related) and PYHIN1 (encoding 
pyrin and HIN domain family, member 1). In contrast, six miRNA-mRNA relationships 
were identified among the up-regulated genes in the patients. For example, hsa-miR-381 
was down-regulated while its potential target gene NFKBIA (encoding nuclear factor of 
kappa light polypeptide gene enhancer in B-cells inhibitor, alpha), was up-regulated in 
the patients. (t-test p=0.00067). Linear regression confirmed the relationships between 
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miRNAs and their potential gene targets (Table 3). Figure 2 shows some examples of the 
confirmed (p<0.05) miRNA-mRNA relationships in the Caucasian American samples.  
Discussion 
 Lung transplantation is associated with major complications such as infection, 
acute rejection and chronic rejection characterized by BOS (2). Elucidating the complex 
cellular and physiological response after lung transplantation will be critical to 
understanding the pathogenesis of acute and chronic complications after lung 
transplantation. To our knowledge, this is the first study to assess the relationship 
between dysregulated genes and potential gene regulators of miRNAs in patients that 
underwent lung transplantation.  
Approximately 3% of the analyzed genes were differentially expressed in 
Caucasian patients with lung transplants, indicating systematical dysregulation of certain 
genes in these patients, potentially implicating their outcomes after lung transplantation. 
Using DAVID (29, 30), these lung transplant-associated genes were found to be enriched 
in a number of known pathways and GO (34) biological processes including “immune 
response”, “defense response”, “response to wounding”, “hemostasis” and “blood 
coagulation” (Table 2). Interestingly, biological processes such as “blood coagulation” 
and “hemostasis” were enriched among down-regulated genes, while biological processes 
such as “immune response”, “defense response”, “response to bacterium”, and “response 
to wounding” were enriched among up-regulated genes. Lung transplant patients are 
routinely anticoagulated to prevent thrombosis, and given antibiotic prophylaxis to 
prevent infections and immunosuppressants to prevent organ rejection. It appears that 
after lung transplantation and relevant treatments, genes related to blood coagulation 
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were significantly down-regulated in patients, while genes related to the aftermath of a 
major surgery including “response to wounding” were significantly up-regulated in 
patients.  
Notably, many of these pathways shared a significant number of genes, displaying 
the complex interactions of several biological processes after lung transplantation. For 
example, all of the seven up-regulated genes including FOS (encoding FBJ murine 
osteosarcoma viral oncogene homolog), IL8 (encoding interleukin 8), IL1B (encoding 
interleukin 1, beta), involved in “inflammatory response” were also involved in “response 
to wounding”. In addition, many genes related to the response to bacterial infection and 
lipopolysaccharide (LPS) were up-regulated in patients such as NFKBIA, FOS, PTGS2 
(encoding prostaglandin-endoperoxide synthase 2), ADM (encoding adrenomedullin), 
SOCS3 (encoding suppressor of cytokine signaling 3), TRIB1 (encoding tribbles homolog 
1) and IL1B. Among them, FOS, PTGS2 and IL1B are genes involved in “response to 
glucocorticoid stimulus”, which was also enriched in the up-regulated genes and likely 
reflected treatment. Besides these up-regulated immune response genes, 20 other immune 
response genes such as CCR4 (encoding chemokine receptor 4), CD86 (encoding CD86 
molecule), were down-regulated in patients. Since lung transplant patients were treated 
continuously with immunosuppressive drugs, the dysregulation of some of these immune 
response genes could be due to the on-going immunosuppressant treatments. Obviously, 
some immune response genes such as FOS, PTGS2, IL1B could be induced by 
immunosuppressive drugs (e.g., glucocorticoids), while some other immune response 
genes could be suppressed by drug treatments. Dysregulation of these genes after 
transplantation provides more insight regarding the interactions of various biological 
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processes and may ultimately provide biomarkers of the various complications related to 
outcomes after transplantation. 
Among the 364 differential genes in patients, a number of genes showed an 
expression pattern correlated with their potential regulating miRNAs (Table 3). Using a 
linear regression model, we demonstrated that expression of specific miRNAs was 
significantly correlated with the expression levels of their potential gene targets. For 
example, ATR and LRRC8B (encoding leucine rich repeat containing 8 family, member B) 
were down-regulated in transplant patients. Their expression levels were significantly 
correlated with their potential regulating miRNA, respectively (Figure 2). The majority 
of the identified miRNA-mRNA relations could be confirmed using linear regression.  
Notably, the gene NFKBIA was found to be negatively associated with its potential 
regulating miRNA has-miR-381 (Table 3). NFKBIA is also involved in “response to 
wounding” and “response to LPS”, suggesting that miRNAs may contribute to these 
biological processes in lung transplant patients. Our results suggest that the complex 
dynamics of dysregulated genes in these patients may be partially attributed to the 
differential expression of their potential regulating miRNAs following lung 
transplantation, as well as relevant treatments such as immunosuppressive drugs, 
anticoagulants.  
We recognize that there are some limitations to this exploratory study.  Firstly, the 
sample size of the population was small and therefore, this analysis must be validated 
with a larger cohort of patients. Secondly, some potential confounding factors (e.g., types 
of immunosuppressive agent that the patients are taking) might influence gene 
dysregulation. In addition, we were unable to compare our findings between different 
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ethnic populations, as well as derive more robust conclusions for BOS-associated 
dysregulation, given the small sample size.  However, given the exploratory nature of this 
analysis, our primary goal was to determine the putative relationships between 
dysregulated genes and regulating microRNAs in lung transplantation.  Indeed, we were 
able to show a significant number of miRNA-mRNA relationships, suggesting that the 
regulation of gene targets by these miRNAs in the context of lung transplantation warrant 
further investigation, and could ultimately provide as novel therapeutic targets in lung 
transplant complications.  
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Table 1.  Summary of the study cohort.  
 
F, female; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary 
fibrosis; SLT, single-lung transplant; BSL, bilateral single-lung transplant; BOS, 
bronchiolitis obliterans syndrome; PLCH, Pulmonary Langerhans Cell Histiocytosis; CTD, connective 
tissue disease; ITD, interstitial lung disease 
 
 Caucasian Caucasian 
controls 
African 
American 
African 
American 
controls 
Age (mean + SD) years 56 + 18 65 + 12 48+ 9 75 + 7 
Gender (F) (%) 3 (21%) 6 (22%) 2 (50%) 5 (63%) 
Underlying Diagnosis 
COPD 
IPF 
CF 
Bronchiectasis 
Sarcoidosis 
PLCH 
CTD-ILD 
 
 
4 
7 
1 
1 
 
1 
--  
1 
1 
0 
0 
1 
0 
1 
-- 
Type of transplant 
SLT 
BLT 
 
8 
6 
--  
1 
3 
-- 
Time from transplant 
(mean + SD) months 
10.4 + 9.1 -- 11+ 4 -- 
BOS 5 (36%) -- 1 (25%) -- 
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Table 2.  Some enriched pathways and biological processes among the dysregulated genes in Caucasian American patients. 
 
Gene Group Pathway Category Count P Fold Enrichment FDR 
GO:0009617~response to bacterium 16 1.09E-06 4.74 0.002 
GO:0006955~immune response 33 1.39E-06 2.56 0.001 
REACT_604:Hemostasis 20 3.31E-05 2.81 0.001 
GO:0009611~response to wounding 26 8.98E-05 2.37 0.054 
all 
  
  
GO:0006952~defense response 26 1.40E-04 2.31 0.063 
REACT_604:Hemostasis 18 4.50E-05 2.96 0.002 
GO:0050817~coagulation 10 6.18E-05 5.61 0.083 
GO:0007596~blood coagulation 10 6.18E-05 5.61 0.083 
down-regulated 
 
GO:0007599~hemostasis 10 7.70E-05 5.46 0.052 
GO:0009617~response to bacterium 10 4.11E-08 13.25 0.000 
GO:0006955~immune response 13 1.77E-05 4.52 0.004 
GO:0006952~defense response 12 2.76E-05 4.76 0.005 
GO:0007610~behavior 10 8.23E-05 5.30 0.009 
GO:0010033~response to organic substance 12 5.42E-04 3.41 0.040 
up-regulated 
  
  
 
  
GO:0009611~response to wounding 10 5.80E-04 4.08 0.040 
GO, Gene Ontology biological process; REACT, Reactome pathway; FDR, false discovery rate 
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Table 3.  Some dysregulated genes in the Caucasian American patients are negatively associated with potential regulating miRNAs. 
 
Gene 
Class 
Target 
Gene Gene Title microRNA p (miRanda)a p (t-test)b 
p (linear 
regression)c 
r2 (linear 
regression)d 
TCF4 transcription factor 4 hsa-miR-299-3p 0.000031 0.012 0.035 0.11 
LRRC8B 
leucine rich repeat containing 8 
family, member B hsa-miR-29b-1* 0.000056 0.019 0.0057 0.20 
C14orf2 
chromosome 14 open reading 
frame 2 hsa-miR-34a 0.000058 0.0001 0.042 0.11 
FUT8  fucosyltransferase 8 hsa-miR-34a 0.0000003 0.0001 0.0084 0.17 
C14orf135 
chromosome 14 open reading 
frame 135  hsa-miR-451 0.0000086 0.0064 0.011 0.16 
ATR 
 ataxia telangiectasia and Rad3 
related hsa-miR-519e 0.0000075 0.0031 0.0046 0.19 
PYHIN1 
 pyrin and HIN domain family, 
member 1 hsa-miR-519e 0.000091 0.0031 0.0074 0.17 
down-
regulated  
  
  
  
  
  
  
TCF4  transcription factor 4 hsa-miR-629 0.0000071 0.022 0.045 0.12 
CA1  carbonic anhydrase I hsa-miR-590-5p 0.000052 0.00067  NS   
NFKBIA 
 nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, alpha hsa-miR-381 0.000021 0.0012  0.023  0.13 
NFIL3 
 nuclear factor, interleukin 3 
regulated hsa-miR-374a 0.000046 0.011  NS   
DOCK4 dedicator of cytokinesis 4 hsa-miR-28-5p 0.000095 0.012  NS   
PLK2  polo-like kinase 2 hsa-miR-126 0.000055 0.025  NS   
up-
regulated 
  
PLK2  polo-like kinase 2 hsa-miR-27b 0.000000088 0.033  NS   
 
a: p-values from the miRanda algorithm; b: p-values by comparing miRNA expression levels between patients and normal controls; c: p-values from linear 
regression tests on the relationships between miRNAs and target genes; NS, not significant; d: correlation coefficients from the linear regression tests 
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Figure Legends 
 
Figure 1. Genes dyregulated in the Caucasian American lung transplant patients. 
In total, 364 genes were differentially expressed between lung transplant patients and 
normal controls. Among them, 292 genes were down-regulated in the patients, while 72 
genes were up-regulated in the patients. Blue represents down-regulation. Red represents 
up-regulation. Red bars: controls; Green bars: lung transplant patients. 
 
 
 
Figure 2. Examples of the relationships between potential regulating miRNAs and 
the dysregulated genes. 
The p-values were from linear regression tests.  Blue dots represent the control samples. 
Red dots represent the patient samples. X-axis: miRNA expression; Y-axis: mRNA 
expression. (A). ATR (encoding ataxia telangiectasia and Rad3 related) was down-
regulated in the patients; (B). LRRC8B (encoding leucine rich repeat containing 8 family, 
member B) was down-regulated in the patients; (C). PYHIN1 (encoding pyrin and HIN 
domain family, member 1) as down-regulated in the patients; and (D). NFKBIA was up-
regulated in the patients. 
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